Dexmedetomidine as an Additive for (Ipack)Block in Knee Surgery
Analgesic Effect of Using Dexmedetomidine as an Additive for (Ipack)Block in Knee Surgeries in Adult Patient; A Randomized Controlled Trial
1 other identifier
interventional
40
1 country
1
Brief Summary
Dexmedetomidine used as an Additive for Ipack Block in Knee Surgery
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable
Started Jan 2024
Shorter than P25 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 2, 2024
CompletedFirst Submitted
Initial submission to the registry
May 5, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 10, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
July 30, 2024
CompletedFirst Posted
Study publicly available on registry
July 10, 2025
CompletedJuly 10, 2025
June 1, 2025
6 months
May 5, 2024
June 30, 2025
Conditions
Outcome Measures
Primary Outcomes (1)
Visual Analog Scale at rest score during first postoperative 48 hours
Visual Analog Scale at rest during first postoperative 48 hours a line 10centimeters long from zero to10 where 10 is the worst pain ever
48 postoperative hours
Secondary Outcomes (6)
Visual Analog Scale at rest and during movement at 30 minuts, 2, 8, 16, 24, 36, and 48 hours
48 postoperative hours
Duration of the block
48 hours
Heart Rate
48 hours
Mean Arterial Pressure
48 hours
Block performance time in minutes
preoperative
- +1 more secondary outcomes
Study Arms (2)
Bupivacaine
EXPERIMENTALIPACK block with 20ml bupivacaine 0.25% alone. .
Dexmedetomidine
EXPERIMENTALIPACK block with 20 ml of bupivacaine 0.25% with dexmedetomidine 100 μg as adjuvant.
Interventions
dexmedetomidine 100 μg as adjuvant to IPACK block with 20 ml of bupivacaine 0.25%.
Eligibility Criteria
You may qualify if:
- years
- ASA I, II .patients undergoing knee surgeries.
You may not qualify if:
- patient Refusal
- bleeding disorders
- skin lesion
- infection
- known allergy
- contradictions of spinal anesthesia
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Cairo Universitylead
Study Sites (1)
Faculty of medicine Cairo university
Cairo, Egypt
MeSH Terms
Interventions
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Dalia K Ismail
Cairo University
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Who Masked
- PARTICIPANT, INVESTIGATOR
- Purpose
- PREVENTION
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Associate Professor of Anesthesia, Surgical ICU and pain management at Faculty of medicine Cairo University
Study Record Dates
First Submitted
May 5, 2024
First Posted
July 10, 2025
Study Start
January 2, 2024
Primary Completion
July 10, 2024
Study Completion
July 30, 2024
Last Updated
July 10, 2025
Record last verified: 2025-06
Data Sharing
- IPD Sharing
- Will not share